Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.9
5.4
Journals
Pharmaceutics
Special Issues
Applications of Mesoporous Silica Nanoparticles (MSNs) in Innovative Drug Delivery...
share announcement

Applications of Mesoporous Silica Nanoparticles (MSNs) in Innovative Drug Delivery and Therapeutics

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".

Deadline for manuscript submissions: closed (31 March 2023) | Viewed by 3577

Special Issue Editors

Dr. Sandra Gago

E-Mail Website
Guest Editor
LAQV-REQUIMTE, Department of Chemistry, NOVA School of Science and Technology, NOVA University Lisbon, Campus da Caparica, 2829-516 Caparica, Portugal
Interests: mesoporous silica nanoparticles; pharmaceutical ionic liquids (API-ILs); drug delivery; photochromic and electrochromic devices; catalysis
Dr. Miguel Santos

E-Mail Website
Guest Editor
Department of Chemistry, Universidade NOVA de Lisboa, Calçada de Alfazina 2, 2825-149 Caparica, Portugal
Interests: active pharmaceutical ingredients as organic salts and ionic liquids; API-OSILs; bioavailability; drug delivery; ionic liquids
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Mesoporous silica nanoparticles (MSNs) offer several advantages in drug formulations. On one hand, they can act as antimicrobial agents  by themselves, with specific activity according to their structure. On the other hand, they can also increase the therapeutic effect of drugs, either by targeted delivery to the disease site or by controlled drug release. In the latter case, nonspecific interactions are minimized, thus lowering side effects and decreasing the required treatment dose. In addition, these nanomaterials have tailored mesoporous structures, large surface area and pore volume, selective surface functionality, morphology control, high loading capacity for therapeutic agents and good biocompatibility.

In this Special Issue, we invite academics and pharmaceutical researchers to bring their new insights into innovative MSN-based methods to improve therapeutic efficacy and controlled drug delivery, among other pharmaceutical applications.

Dr. Sandra Gago
Dr. Miguel Santos
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • controlled drug release
  • drug delivery
  • mesoporous silica nanoparticles
  • MSNs
  • nanomedicine

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

17 pages, 2331 KiB  
Article
In Vitro Antimicrobial Studies of Mesoporous Silica Nanoparticles Comprising Anionic Ciprofloxacin Ionic Liquids and Organic Salts
by Luís Filipe, Telma de Sousa, Dário Silva, Miguel M. Santos, Manuela Ribeiro Carrott, Patrícia Poeta, Luís C. Branco and Sandra Gago
Pharmaceutics 2023, 15(7), 1934; https://doi.org/10.3390/pharmaceutics15071934 - 12 Jul 2023
Cited by 2 | Viewed by 1338
Abstract
The combination of active pharmaceutical ingredients in the form of ionic liquids or organic salts (API-OSILs) with mesoporous silica nanoparticles (MSNs) as drug carriers can provide a useful tool in enhancing the capabilities of current antibiotics, especially against resistant strains of bacteria. In [...] Read more.
The combination of active pharmaceutical ingredients in the form of ionic liquids or organic salts (API-OSILs) with mesoporous silica nanoparticles (MSNs) as drug carriers can provide a useful tool in enhancing the capabilities of current antibiotics, especially against resistant strains of bacteria. In this publication, the preparation of a set of three nanomaterials based on the modification of a MSN surface with cholinium ([MSN-Chol][Cip]), 1-methylimidazolium ([MSN-1-MiM][Cip]) and 3-picolinium ([MSN-3-Pic][Cip]) ionic liquids coupled with anionic ciprofloxacin have been reported. All ionic liquids and functionalized nanomaterials were prepared through sustainable protocols, using microwave-assisted heating as an alternative to conventional methods. All materials were characterized through FTIR, solution 1H NMR, elemental analysis, XRD and N2 adsorption at 77 K. The prepared materials showed no in vitro cytotoxicity in fibroblasts viability assays. The minimum inhibitory concentration (MIC) for all materials was tested against Gram-negative K. pneumoniae and Gram-positive Enterococcus spp., both with resistant and sensitive strains. All sets of nanomaterials containing the anionic antibiotic outperformed free ciprofloxacin against resistant and sensitive forms of K. pneumoniae, with the prominent case of [MSN-Chol][Cip] suggesting a tenfold decrease in the MIC against sensitive strains. Against resistant K. pneumoniae, a five-fold decrease in the MIC was observed for all sets of nanomaterials compared with neutral ciprofloxacin. Against Enterococcus spp., only [MSN-1-MiM][Cip] was able to demonstrate a slight improvement over the free antibiotic. Full article
(This article belongs to the Special Issue Applications of Mesoporous Silica Nanoparticles (MSNs) in Innovative Drug Delivery and Therapeutics)
►▼ Show Figures

Figure 1

16 pages, 3151 KiB  
Article
Characterization of a Mesoporous Silica Nanoparticle Formulation Loaded with Mitomycin C Lipidic Prodrug (MLP) and In Vitro Comparison with a Clinical-Stage Liposomal Formulation of MLP
by Miguel Manzano, Alberto Gabizón and María Vallet-Regí
Pharmaceutics 2022, 14(7), 1483; https://doi.org/10.3390/pharmaceutics14071483 - 17 Jul 2022
Cited by 3 | Viewed by 1725
Abstract
Nanomedicines have revolutionized the treatment of certain types of cancer, as is the case of doxil, liposomal formulation with doxorubicin encapsulated, in the treatment of certain types of ovarian cancer, AIDS-related Kaposi sarcoma, and multiple myeloma. These nanomedicines can improve the performance of [...] Read more.
Nanomedicines have revolutionized the treatment of certain types of cancer, as is the case of doxil, liposomal formulation with doxorubicin encapsulated, in the treatment of certain types of ovarian cancer, AIDS-related Kaposi sarcoma, and multiple myeloma. These nanomedicines can improve the performance of conventional chemotherapeutic treatments, with fewer side effects and better efficiency against cancer. Although liposomes have been used in some formulations, different nanocarriers with better features in terms of stability and adsorption capabilities are being explored. Among the available nanoparticles in the field, mesoporous silica nanoparticles (MSNP) have attracted great attention as drug delivery platforms for the treatment of different diseases. Here, a novel formulation based on MSNP loaded with a potent antitumor prodrug that works in vitro as well as in a clinically evaluated liposomal formulation has been developed. This novel formulation shows excellent prodrug encapsulation efficiency and effective release of the anticancer drug only under certain stimuli typical of tumor environments. This behavior is of capital importance for translating this nanocarrier to the clinic in the near future. Full article
(This article belongs to the Special Issue Applications of Mesoporous Silica Nanoparticles (MSNs) in Innovative Drug Delivery and Therapeutics)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop